Epilepsy Drug Emerges as HRT Alternative
Gabapentin Cools Menopausal Hot Flashes
Jan. 31, 2003 -- A drug traditionally used to treat epilepsy and migraine may be a valuable alternative to hormone replacement therapy (HRT) for postmenopausal women who suffer from hot flashes. A new study shows use of the drug, known generically as gabapentin and sold under the name Neurontin, can reduce both the frequency and severity of hot flashes.
Researchers say hot flashes affect about 75% of postmenopausal women, and women who suffer from hot flashes are also more likely to suffer from sleep and mood disturbances than others. Hormone replacement therapy is one of the few effective treatments for treating these symptoms of menopause, but many women are now looking for alternative treatments in the wake of recent research that has shown HRT can slightly increase the risk of heart disease and breast cancer in some women.
The study, published in the February issue of Obstetrics and Gynecology, compares the effects of gabapentin vs. a placebo in relieving hot flashes.
Researchers randomly assigned a group of 59 postmenopausal women who suffered from seven or more hot flashes a day to receive either the drug or a placebo for 12 weeks. During that period, the women kept a diary to record their hot flash frequency and severity.
The study found that women who took a low dose of the drug (900 mg/day) reported a 54% reduction in overall hot flash activity (both frequency and severity) compared with a 31% drop in the placebo group.
After the study ended, the women were also given the opportunity to participate in a five-week extended trial in which they took higher doses of the drug (up to 2,700 mg/day). Researchers found these higher doses were associated with an even higher reduction (up to 67%) in hot flash activity.
"It's very exciting to have an effective, non-hormonal hot flash treatment for women who have chosen to discontinue their hormone replacement therapy," says researcher Thomas L. Guttuso Jr., MD, a neurologist at the University of Rochester Medical Center, in a news release.
Gabapentin is FDA-approved for the treatment of epilepsy and shingles pain, but it is also frequently used to treat migraine headache, panic disorder, and social phobia. Side effects of the drug include sleepiness, dizziness, and leg swelling. About 13% of the women in the study dropped out because of side effects.